For mutations amenable to exon 44 skipping, the FDA designates Duchenne Agent AOC 1044 as a Rare Pediatric Disease.

Published Date: 23 May 2024

In the second part of 2024, Avidity Biosciences plans to release new cohort data from the phase 1/2 EXPLORE44 trial, which evaluated AOC 1044 in Duchenne muscular dystrophy mutations susceptible to exon 44 skipping.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot